Cargando…
Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
In several randomized studies, remdesivir (RDV) has been reported to shorten the recovery period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as a standard of care. Nevertheless, controversial reports have been published. The aim of the present study is to evaluate...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611983/ https://www.ncbi.nlm.nih.gov/pubmed/36296225 http://dx.doi.org/10.3390/microorganisms10101949 |
_version_ | 1784819663782281216 |
---|---|
author | Petrakis, Vasilis Rapti, Vasiliki Akinosoglou, Karolina Bonelis, Constantinos Athanasiou, Kalomoira Dimakopoulou, Vasiliki Syrigos, Nikolaos K. Spernovasilis, Nikolaos Trypsianis, Grigoris Marangos, Markos Gogos, Charalambos Papazoglou, Dimitrios Panagopoulos, Periklis Poulakou, Garyfallia |
author_facet | Petrakis, Vasilis Rapti, Vasiliki Akinosoglou, Karolina Bonelis, Constantinos Athanasiou, Kalomoira Dimakopoulou, Vasiliki Syrigos, Nikolaos K. Spernovasilis, Nikolaos Trypsianis, Grigoris Marangos, Markos Gogos, Charalambos Papazoglou, Dimitrios Panagopoulos, Periklis Poulakou, Garyfallia |
author_sort | Petrakis, Vasilis |
collection | PubMed |
description | In several randomized studies, remdesivir (RDV) has been reported to shorten the recovery period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as a standard of care. Nevertheless, controversial reports have been published. The aim of the present study is to evaluate the effectiveness of remdesivir in hospitalized patients with COVID-19 pneumonia at three Greek University Departments of Infectious Diseases with homogenous treatment protocols. From September 2020 to February 2021, we retrospectively analyzed adults hospitalized with confirmed SARS-CoV-2 infection and radiological findings of pneumonia, who received remdesivir once daily for five days. Exploratory end points were duration of hospitalization, time of intubation, and death. Overall, 551 patients were included in the study. The optimal cutoff point for the number of days needed after symptom initiation for drug administration associated with better clinical outcome was 7 days. Higher odds for discharge and lower for intubation were observed in patients with treatment initiation ≤7 days (p = 0.052 and p = 0.019, retrospectively) regardless of gender (p = 0.537), hypertension (p = 0.096), dyslipidemia (p = 0.221), diabetes mellitus (p = 0.306), and usage of immunomodulators (p = 0.408). Our study has demonstrated beneficial effects of early treatment with remdesivir (≤7 days from symptom onset) on rates of intubation and probability of discharge. |
format | Online Article Text |
id | pubmed-9611983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96119832022-10-28 Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia Petrakis, Vasilis Rapti, Vasiliki Akinosoglou, Karolina Bonelis, Constantinos Athanasiou, Kalomoira Dimakopoulou, Vasiliki Syrigos, Nikolaos K. Spernovasilis, Nikolaos Trypsianis, Grigoris Marangos, Markos Gogos, Charalambos Papazoglou, Dimitrios Panagopoulos, Periklis Poulakou, Garyfallia Microorganisms Article In several randomized studies, remdesivir (RDV) has been reported to shorten the recovery period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as a standard of care. Nevertheless, controversial reports have been published. The aim of the present study is to evaluate the effectiveness of remdesivir in hospitalized patients with COVID-19 pneumonia at three Greek University Departments of Infectious Diseases with homogenous treatment protocols. From September 2020 to February 2021, we retrospectively analyzed adults hospitalized with confirmed SARS-CoV-2 infection and radiological findings of pneumonia, who received remdesivir once daily for five days. Exploratory end points were duration of hospitalization, time of intubation, and death. Overall, 551 patients were included in the study. The optimal cutoff point for the number of days needed after symptom initiation for drug administration associated with better clinical outcome was 7 days. Higher odds for discharge and lower for intubation were observed in patients with treatment initiation ≤7 days (p = 0.052 and p = 0.019, retrospectively) regardless of gender (p = 0.537), hypertension (p = 0.096), dyslipidemia (p = 0.221), diabetes mellitus (p = 0.306), and usage of immunomodulators (p = 0.408). Our study has demonstrated beneficial effects of early treatment with remdesivir (≤7 days from symptom onset) on rates of intubation and probability of discharge. MDPI 2022-09-30 /pmc/articles/PMC9611983/ /pubmed/36296225 http://dx.doi.org/10.3390/microorganisms10101949 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Petrakis, Vasilis Rapti, Vasiliki Akinosoglou, Karolina Bonelis, Constantinos Athanasiou, Kalomoira Dimakopoulou, Vasiliki Syrigos, Nikolaos K. Spernovasilis, Nikolaos Trypsianis, Grigoris Marangos, Markos Gogos, Charalambos Papazoglou, Dimitrios Panagopoulos, Periklis Poulakou, Garyfallia Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia |
title | Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia |
title_full | Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia |
title_fullStr | Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia |
title_full_unstemmed | Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia |
title_short | Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia |
title_sort | greek remdesivir cohort (grec) study: effectiveness of antiviral drug remdesivir in hospitalized patients with covid-19 pneumonia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611983/ https://www.ncbi.nlm.nih.gov/pubmed/36296225 http://dx.doi.org/10.3390/microorganisms10101949 |
work_keys_str_mv | AT petrakisvasilis greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT raptivasiliki greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT akinosogloukarolina greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT bonelisconstantinos greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT athanasioukalomoira greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT dimakopoulouvasiliki greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT syrigosnikolaosk greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT spernovasilisnikolaos greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT trypsianisgrigoris greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT marangosmarkos greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT gogoscharalambos greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT papazogloudimitrios greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT panagopoulosperiklis greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia AT poulakougaryfallia greekremdesivircohortgrecstudyeffectivenessofantiviraldrugremdesivirinhospitalizedpatientswithcovid19pneumonia |